Screener
CorMedix CRMD EPS (Diluted)
Discontinued — last reported Q1 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: CorMedix’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Unrealized loss from investments | (1) | (5) |
| Foreign currency translation loss | - | (1) |
| Total Other Comprehensive Loss | (1) | (6) |
| Comprehensive Income | $38,600 | $20,638 |
| Net Income Per Common Share – Basic | $0.48 | $0.32 |
| Net Income Per Common Share - Diluted | $0.43 | $0.30 |
| Weighted Average Common Shares Outstanding – Basic | 79,509 | 65,244 |
| Weighted Average Common Shares Outstanding – Diluted | 92,985 | 68,975 |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's EPS (diluted)?
- CorMedix (CRMD) reported EPS (diluted) of $0.43 in Q1 2026.
- How has CorMedix's EPS (diluted) changed year-over-year?
- CorMedix's EPS (diluted) increased by 43.3% year-over-year, from $0.30 to $0.43.
- What is the long-term trend for CorMedix's EPS (diluted)?
- Over 3 years (2021 to 2025), CorMedix's EPS (diluted) has grown at a 36.6% compound annual growth rate (CAGR), from -$0.75 to $1.91.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about CorMedix's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude